The use of nanotechnology in Abraxane addresses several limitations of conventional chemotherapy. Firstly, paclitaxel is poorly soluble in water, which makes it challenging to administer in its pure form. Traditional formulations use solvents that can cause severe side effects. By binding paclitaxel to albumin nanoparticles, Abraxane avoids the need for these toxic solvents. Additionally, the enhanced permeability and retention (EPR) effect allows the nanoparticles to accumulate more in tumor tissues than in normal tissues, increasing the drug's efficacy and reducing systemic toxicity.
